hotspot -WSS

hotspot

author：leisure time 2025-09-30 17:59:52 - browse：617

Photo illustration of Fyodor Urnov surrounded by DNA strands. -- health coverage from STAT — Christine Kao/STAT

Researchers attending gene therapy meetings over the past couple years were liable to bump into a svelte, graying scientist explaining in emphatic, Russian-inflected English that the U.S. was wasting the grand potential of CRISPR gene editing.

Fyodor Urnov, the scientist in question, estimates he gave the talk 30 to 40 times: to fellow researchers, pharma executives, Food and Drug Administration officials, congressional staff, journalists, patient advocates. “Anyone who would listen,” he says.

The problem was one of scale. Sure, for-profit companies were developing cures for a small handful of genetic diseases, such as sickle cell disease. But there were hundreds of devastating conditions that CRISPR might be able to cure but that no entity was seriously working on.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Element Biosciences CEO lays out genome sequencing strategy

WSS

Getting Alzheimer's drug Leqembi to patients can be a challenge

UnitedHealth financials solid despite Change Healthcare cyberattack

Philips to halt sales of sleep apnea machines in U.S.

Bird flu outbreak in cows is latest avian flu curveball

Reconstructing family trees of blood cells may help predict disease

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

explore

hotspot

focus

The high cost of giving birth even with insurance

Philips to halt sales of sleep apnea machines in U.S.

In Memoriam: Notable people who died in 2023

Cancer researcher Catriona Jamieson is sending tumors into space

United colonoscopy coverage change 'may cost lives,' doctors say

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Dogs on Prozac: What pet anti

BioMarin wins approval for gene therapy to treat hemophilia A

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

focus

Why you shouldn’t ask, “What country has the best health care?”

Getting Alzheimer's drug Leqembi to patients can be a challenge

Investment in vaccine development is lagging, report finds

Bird flu outbreak in cows is latest avian flu curveball

Health care needs a new profession: neuroimaging counseling

Bird flu outbreak in cows is latest avian flu curveball

hotspot

hotspot

knowledge

explore